NGM-438

NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays[1].

Product Specifications

UNSPSC

12352203

Target

MMP

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer

Purity

99.74

Molecular Weight

(144.92 kDa)

References & Citations

[1]Sisi He, et al. Preclinical development of NGM438, a novel anti-LAIR1 antagonist monoclonal antibody for the treatment of collagen-rich solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA) : AACR; Cancer Res 2022;82 (12_Suppl) :Abstract nr LB219.